RPM Cost Sharing Elimination Study Act of 2023

Bill 118 hr 6801, also known as the RPM Cost Sharing Elimination Study Act of 2023, is a piece of legislation introduced in the US Congress. The purpose of this bill is to conduct a study on the elimination of cost-sharing requirements for prescription drugs covered under the Medicare Prescription Drug Benefit Program, also known as Medicare Part D.

The bill aims to analyze the potential impact of eliminating cost-sharing requirements for prescription drugs on Medicare beneficiaries, including the potential cost savings and health outcomes. The study would also examine the feasibility and potential challenges of implementing such a policy change.

Additionally, the bill calls for the study to evaluate the impact of eliminating cost-sharing requirements on Medicare Part D plan sponsors, pharmaceutical manufacturers, and other stakeholders in the healthcare industry. The study would be conducted by the Secretary of Health and Human Services in consultation with relevant stakeholders. Overall, the RPM Cost Sharing Elimination Study Act of 2023 seeks to gather data and information to inform policymakers on the potential benefits and challenges of eliminating cost-sharing requirements for prescription drugs under Medicare Part D. This bill reflects ongoing efforts to improve access to affordable healthcare for Medicare beneficiaries.